Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 524

1.

Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.

Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR.

Am J Cardiol. 2008 Feb 15;101(4):490-6. doi: 10.1016/j.amjcard.2007.09.099. Epub 2007 Dec 20.

PMID:
18312764
2.

Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.

Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.

Clin Ther. 2008 Jan;30(1):84-97. doi: 10.1016/j.linthera.2008.01.013.

PMID:
18343245
3.

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.

Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B.

Curr Med Res Opin. 2004 Sep;20(9):1437-45.

PMID:
15383192
4.
6.

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.

Ballantyne CM, Pazzucconi F, Pintó X, Reckless JP, Stein E, McKenney J, Bortolini M, Chiang YT.

Clin Ther. 2001 Feb;23(2):177-92.

PMID:
11293552
7.

Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study).

Ilerigelen B, Uresin Y, San M, Kültürsay H, Güneri S, Serdar OA, Güleç S, Pençedemir H; TULIPS Investigators.

Curr Med Res Opin. 2007 May;23(5):1093-102.

PMID:
17519076
8.

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B; Ezetimibe Study Group.

Am J Cardiol. 2002 Nov 15;90(10):1084-91.

PMID:
12423708
10.

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.

Olsson AG, Pauciullo P, Soska V, Luley C, Pieters RE, Broda G, Palacios B; Fluvastatin Study Group.

Clin Ther. 2001 Jan;23(1):45-61.

PMID:
11219479
11.

Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.

Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E; Ezetimibe Study Group.

J Womens Health (Larchmt). 2004 Dec;13(10):1101-7.

PMID:
15650343
13.

Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.

Masana L, Mata P, Gagné C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, Troxell JK, Gumbiner B; Ezetimibe Study Group.

Clin Ther. 2005 Feb;27(2):174-84.

PMID:
15811480
14.

Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).

Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E; EXPLORER Study Investigators.

Am J Cardiol. 2007 Mar 1;99(5):673-80. Epub 2007 Jan 4.

PMID:
17317370
15.

Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia.

Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, Strony J, Suresh R, Veltri E; Ezetimibe Study Group.

Int J Clin Pract. 2004 Aug;58(8):746-55.

PMID:
15372846
16.

Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.

Betteridge DJ, Durrington PN, Fairhurst GJ, Jackson G, McEwan MS, McInnes GT, Miller JP, Mir MA, Reckless JP, Rees-Jones DI, et al.

Am J Med. 1994 Jun 6;96(6A):45S-54S.

PMID:
8017467
17.

Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy.

González CA, Rubio-Guerra AF, Pavía A, Redding FJ, Cervantes JL, Zacarías JL, Yza R, Carranza J, Fernández P, Morales E, Robles FJ, Leyva JL, Rodríguez L.

Clin Drug Investig. 2007;27(5):333-7.

PMID:
17451281
18.

Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study.

Sawayama Y, Maeda S, Ohnishi H, Hayashi S, Hayashi J.

Clin Drug Investig. 2010;30(3):157-66. doi: 10.2165/11531530-000000000-00000.

PMID:
20155988
19.

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy.

Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL.

Curr Med Res Opin. 2007 Aug;23(8):2009-26.

PMID:
17659159
20.

Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.

Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM.

Am J Cardiol. 2009 Feb 1;103(3):369-74. doi: 10.1016/j.amjcard.2008.09.090. Epub 2008 Oct 30.

PMID:
19166691

Supplemental Content

Support Center